Histone deacetylase inhibitors deplete myeloid-derived suppressor cells induced by 4T1 mammary tumors in vivo and in vitro

Cancer Immunology, Immunotherapy

Volumn 66, Issue 3, 2017, Pages 355-366

  Wang, Hai Fang ^a   Ning, Fen ^b   Liu, Zong Cai ^b   Wu, Long ^c   Li, Zi Qian ^a   Qi, Yi Fei ^a   Zhang, Ge ^a   Wang, Hong Sheng ^a   Cai, Shao Hui ^c   Du, Jun ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c JINAN UNIVERSITY   (China)

Author keywords

Apoptosis; Histone deacetylase inhibitors; MDSC; ROS; Sodium butyrate; Vorinostat

Indexed keywords

ACETYLCYSTEINE; BETA ACTIN; BUTYRIC ACID; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; PERFORIN; REACTIVE OXYGEN METABOLITE; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; VORINOSTAT; HISTONE DEACETYLASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD; BREAST TUMOR; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL INFILTRATION; CELL POPULATION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SPACE; LYMPHOCYTE PROLIFERATION; MOUSE; MYELOID-DERIVED SUPPRESSOR CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL PROLIFERATION; DRUG EFFECTS; ENZYMOLOGY; MAMMARY NEOPLASMS, EXPERIMENTAL; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HISTONE DEACETYLASE INHIBITORS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MYELOID-DERIVED SUPPRESSOR CELLS;

EID: 85000893376     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-016-1935-1     Document Type: Article

References (35)

1. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9(3):162–174. doi:10.1038/nri2506
2. Youn J-I, Nagaraj S, Collazo M, Gabrilovich DI (2008) Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 181(8):5791–5802. doi:10.4049/jimmunol.181.8.5791
3. Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P, Mandruzzato S, Bronte V (2010) Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 22(2):238–244. doi:10.1016/j.coi.2010.01.021
4. Gabrilovich DI, Bronte V, Chen S-H, Colombo MP, Ochoa A, Ostrand-Rosenberg S, Schreiber H (2007) The terminology issue for myeloid-derived suppressor cells. Cancer Res 67(1):425. doi:10.1158/0008-5472.can-06-3037
5. + T cells. J Clin Invest 116(10):2777–2790. doi:10.1172/jci28828
6. Ochoa AC, Zea AH, Hernandez C, Rodriguez PC (2007) Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 13(2):721s–726s. doi:10.1158/1078-0432.ccr-06-2197
7. Serafini P, De Santo C, Marigo I, Cingarlini S, Dolcetti L, Gallina G, Zanovello P, Bronte V (2004) Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother 53(2):64–72. doi:10.1007/s00262-003-0443-2
8. Bronte V, Serafini P, Apolloni E, Zanovello P (2001) Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J Immunother 24(6):431–446
9. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V (2008) Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 222(1):162–179. doi:10.1111/j.1600-065X.2008.00602.x
10. Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, Dolcetti L, Bronte V, Borrello I (2006) Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 203(12):2691–2702. doi:10.1084/jem.20061104
11. Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY (2010) A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res 16(18):4583–4594. doi:10.1158/1078-0432.ccr-10-0733
12. Alizadeh D, Trad M, Hanke NT, Larmonier CB, Janikashvili N, Bonnotte B, Katsanis E, Larmonier N (2014) Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Res 74(1):104–118. doi:10.1158/0008-5472.can-13-1545
13. + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 11(18):6713–6721. doi:10.1158/1078-0432.ccr-05-0883
14. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, Martin F, Apetoh L, Rébé C, Ghiringhelli F (2010) 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 70(8):3052–3061. doi:10.1158/0008-5472.can-09-3690
15. Khan AN, Gregorie C, Tomasi T (2008) Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer Immunol Immunother 57(5):647–654. doi:10.1007/s00262-007-0402-4
16. Marks PA, Richon VM, Breslow R, Rifkind RA (2001) Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 13(6):477–483
17. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5(9):769–784
18. Maeda T, Towatari M, Kosugi H, Saito H (2000) Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood 96(12):3847–3856
19. Magner WJ, Kazim AL, Stewart C, Romano MA, Catalano G, Grande C, Keiser N, Santaniello F, Tomasi TB (2000) Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J Immunol 165(12):7017–7024. doi:10.4049/jimmunol.165.12.7017
20. + T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination. J Mol Med 91(10):1221–1231. doi:10.1007/s00109-013-1054-9
21. Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger BZ, Vonderheide RH (2012) Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 21(6):822–835. doi:10.1016/j.ccr.2012.04.025
22. Otaegui D, Rodríguez-Gascón A, Zubia A, Cossío FP, Pedraz JL (2009) Pharmacokinetics and tissue distribution of Kendine 91, a novel histone deacetylase inhibitor, in mice. Cancer Chemother Pharmacol 64(1):153–159. doi:10.1007/s00280-008-0857-9
23. Egorin JM, Yuan Z-M, Sentz LD, Plaisance K, Eiseman LJ (1999) Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats. Cancer Chemother Pharmacol 43(6):445–453. doi:10.1007/s002800050922
24. Jiang G-M, He Y-W, Fang R, Zhang G, Zeng J, Yi Y-M, Zhang S, Bu X-Z, Cai S-H, Du J (2010) Sodium butyrate down-regulation of indoleamine 2,3-dioxygenase at the transcriptional and post-transcriptional levels. Int J Biochem Cell Biol 42(11):1840–1846. doi:10.1016/j.biocel.2010.07.020
25. Jiang G-M, Wang H-S, Zhang F, Zhang K-S, Liu Z-C, Fang R, Wang H, Cai S-H, Du J (2013) Histone deacetylase inhibitor induction of epithelial–mesenchymal transitions via up-regulation of Snail facilitates cancer progression. Biochim Biophys Acta 1833(3):663–671. doi:10.1016/j.bbamcr.2012.12.002
26. Dokmanovic M, Marks PA (2005) Prospects: histone deacetylase inhibitors. J Cell Biochem 96(2):293–304. doi:10.1002/jcb.20532
27. Rosato R, Almenara J, Grant S (2003) The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 63(13):3637–3645
28. Mundy-Bosse BL, Lesinski GB, Jaime-Ramirez AC, Benninger K, Khan M, Kuppusamy P, Guenterberg K, Kondadasula SV, Chaudhury AR, La Perle KM, Kreiner M, Young G, Guttridge DC, Carson WE (2011) Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. Cancer Res 71(15):5101–5110. doi:10.1158/0008-5472.can-10-2670
29. Ma C, Kapanadze T, Gamrekelashvili J, Manns MP, Korangy F, Greten TF (2012) Anti-Gr-1 antibody depletion fails to eliminate hepatic myeloid-derived suppressor cells in tumor-bearing mice. J Leukoc Biol 92(6):1199–1206. doi:10.1189/jlb.0212059
30. Kusmartsev S, Cheng F, Yu B, Nefedova Y, Sotomayor E, Lush R, Gabrilovich D (2003) All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res 63(15):4441–4449
31. van der Most R, Currie A, Mahendran S, Prosser A, Darabi A, Robinson BS, Nowak A, Lake R (2009) Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy. Cancer Immunol Immunother 58(8):1219–1228. doi:10.1007/s00262-008-0628-9
32. Rosborough BR, Castellaneta A, Natarajan S, Thomson AW, Turnquist HR (2012) Histone deacetylase inhibition facilitates GM-CSF-mediated expansion of myeloid-derived suppressor cells in vitro and in vivo. J Leukoc Biol 91(5):701–709. doi:10.1189/jlb.0311119
33. Ostrand-Rosenberg S (2010) Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 59(10):1593–1600. doi:10.1007/s00262-010-0855-8
34. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira J-P, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, Andre F, Delaloge S, Tursz T, Kroemer G, Zitvogel L (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13(9):1050–1059
35. Ferrara FF, Fazi F, Bianchini A, Padula F, Gelmetti V, Minucci S, Mancini M, Pelicci PG, Coco FL, Nervi C (2001) Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res 61(1):2–7